A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Trial Profile

A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHAMPION-1
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 14 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
    • 01 Mar 2017 Data will be presented at at the 16th International Myeloma Workshop (IMW), according to an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top